JEFFREY S. MATHIESEN - Corporate Board Profile

Panbela Therapeutics, Inc.

Filing Date	Source Excerpt
2016-04-11	Jeffrey S. Mathiesen has served as a director of our Company since September 2015. Our Board of Directors has determined that Messrs. Gill, Mathiesen, Paulson, Schaffer and Schemel are “independent directors” as defined under the applicable rules of The NASDAQ Stock Market. Jeffrey S. Mathiesen is Chair of the Audit Committee.
2017-04-27	Jeffrey S. Mathiesen has served as a director of our Company since September 2015... Committees: Jeffrey S. Mathiesen - Chair of Audit Committee, member of Nominating and Governance Committee. Non-Employee Director Compensation for 2016: Jeffrey S. Mathiesen - $198,000 total compensation.
2017-08-22	Executive Officers and Directors Jeffrey S. Mathiesen 156,000 Consists of 156,000 shares subject to stock options.
2018-04-16	Jeffrey S. Mathiesen has served as a director of our Company since September 2015... Jeffrey S. Mathiesen serves as Chair of the Audit Committee and is a member of the Nominating and Governance Committee. Directors who are also our employees receive no additional compensation for serving on our Board of Directors. Our non-employee directors received no compensation during the year ended December 31, 2017.
2019-04-16	Jeffrey S. Mathiesen, Director, Age 58. Serves as Chair of Audit Committee and member of Nominating and Governance Committee. No compensation for 2018 as non-employee director.
2020-04-20	Jeffrey S. Mathiesen has served as a director of our Company since September 2015. On March 19, 2019 Mr. Mathiesen selected to service as the Vice Chair and lead independent director for the Company.
2021-04-15	Jeffrey S. Mathiesen has served as a director of our Company since September 2015. Mr. Mathiesen also serves as a director and audit committee chairman of NeuroOne Medical Technologies Corporation, a publicly traded medical device company. Additionally, Mr. Mathiesen serves as a director and audit committee chairman of Helius Medical Technologies, Inc., a publicly traded medical technology company focused on neurological wellness and served as a director and audit committee chairman of eNeura, Inc., a privately held medical technology company providing therapy for both acute treatment and prevention of migraine from July 2018 to February 2020. He has served as Advisor to the CEO of Teewinot Life Sciences, a privately held biopharmaceutical company focused on the biosynthetic production of pure pharmaceutical grade cannabinoids from October 2019 to December 2019, and as Chief Financial Officer from March 2019 to October 2019. In August 2020, Teewinot Life Sciences filed a voluntary petition under Chapter 11 of the United States Bankruptcy Code. Previously he served as Chief Financial Officer of Gemphire Therapeutics Inc., a publicly traded biopharmaceutical company from September 2015 to September 2018. From August 2015 to September 2015, he was a consultant to Gemphire. He served as Chief Financial Officer of Sunshine Heart, Inc., a publicly traded medical device company, from March 2011 to January 2015. Mr. Mathiesen has held executive positions with publicly traded companies dating back to 1993, including vice president and chief financial officer positions. Mr. Mathiesen holds a B.S. in Accounting from the University of South Dakota and is also a Certified Public Accountant.
2022-04-29	Jeffrey S. Mathiesen 61 Vice Chair and Lead Independent Director
2023-04-28	Jeffrey S. Mathiesen 62 Vice Chair and Lead Independent Director ... In March 2020, our Board designated Mr. Mathiesen to serve as its Vice Chair and as lead independent director. ... The membership of each committee is as follows: ... Jeffrey S. Mathiesen Chair Audit, Member Nominating and Governance ... Director Compensation The following table sets forth certain information regarding compensation of the persons who served as our non-employee directors during the most recent completed fiscal year. ... Jeffrey S. Mathiesen 81,500 81,500